Literature DB >> 18690860

Clinical trials: how to assess confounding and why so.

Ton J Cleophas1, Aeilko H Zwinderman.   

Abstract

BACKGROUND: In large randomized controlled trials the risk of random imbalance of the covariates is mostly negligible. However, with smaller studies it may be substantial. In the latter situation assessment and adjustment for confounders is a requirement in order to reduce a biased assessment of the treatment comparison.
OBJECTIVE: In the current paper three methods for confounding assessment and adjustment are reviewed for a nonmathematical readership.
METHODS: First method, subclassification: the study population is divided into subclasses with the same subclass characteristic, then, treatment efficacy is assessed per subclass, and, finally, a weighted average is calculated. Second method, regression modeling: in a multivariable regression model with treatment efficacy as independent and treatment modality as dependent variable, the covariates at risk of confounding are added as additional dependent variables to the model. An analysis adjusted for confounders is obtained by removing the covariates that are not statistically significant. Third method, propensity scores: each patient is assigned several odds ratios (ORs), which are his/her probability, based on his/her covariate value of receiving a particular treatment modality. A propensity score per patient is calculated by multiplying all of the statistically significant ORs. These propensity scores are, then, applied for confounding adjustment using either subclassification or regression analysis.
CONCLUSIONS: The advantages of the first method include that empty subclasses in the treatment comparison are readily visualized, and that subclassification does not rely on a linear or any other regression model. A disadvantage is, that it can only be applied for a single confounder at a time. The advantage of the second method is, that multiple variables can be included in the model. However, the number of covariates is limited by the sample size of the trial. An advantage of the third method is, that it is generally more reliable and powerful with multiple covariates than regression modeling. However, irrelevant covariates and very large / small ORs reduce power and reliability of the assessment. The above methods can not be used for the assessment of interaction in the data.

Entities:  

Mesh:

Year:  2007        PMID: 18690860     DOI: 10.2174/157488407780598162

Source DB:  PubMed          Journal:  Curr Clin Pharmacol        ISSN: 1574-8847


  5 in total

1.  What's new in trial design: propensity scores, equivalence, and non-inferiority.

Authors:  Paul S Myles
Journal:  J Extra Corpor Technol       Date:  2009-12

2.  Evaluation of different approaches for confounding in nonrandomised observational data: a case-study of antipsychotics treatment.

Authors:  E Sarlon; A Millier; S Aballéa; M Toumi
Journal:  Community Ment Health J       Date:  2014-04-03

3.  Disparities in management of new-onset atrial fibrillation in the emergency department despite adherence to the current guidelines: data from a large metropolitan area.

Authors:  Francesco Buccelletti; Salvatore Di Somma; Alberto Galante; Francesco Pugliese; Filippo Alegiani; Giuliano Bertazzoni; Nicolò Gentiloni Silveri; Jacopo M Legramante; Francesco Franceschi
Journal:  Intern Emerg Med       Date:  2011-02-13       Impact factor: 3.397

4.  Echocardiographic assessment of functional mitral regurgitation: opening Pandora's box?

Authors:  Andreas Hagendorff; Torsten Doenst; Volkmar Falk
Journal:  ESC Heart Fail       Date:  2019-07-25

5.  Evidence-based new service package vs. routine service package for smoking cessation to prevent high risk patients from cardiovascular diseases (CVD): study protocol for randomized controlled trial.

Authors:  Myo Nyein Aung; Motoyuki Yuasa; Thaworn Lorga; Saiyud Moolphate; Hiroshi Fukuda; Tsutomu Kitajima; Hirohide Yokokawa; Kazuo Minematsu; Susumu Tanimura; Yoshimune Hiratsuka; Koichi Ono; Prissana Naunboonruang; Payom Thinuan; Sachio Kawai; Yaoyanee Suya; Somboon Chumvicharana; Eiji Marui
Journal:  Trials       Date:  2013-12-05       Impact factor: 2.279

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.